H3N2 Influenza Viruses in Humans: Viral Mechanisms, Evolution, and Evaluation

Viral Infections, Non-HIV

Anti-influenza virus activity of a salcomine derivative mediated by inhibition of viral RNA synthesis

Arch Virol.

Takizawa N, Kimura T, Watanabe T, Shibasaki M

doi: 10.1007/s00705-018-3779-9.

Viral Infections, Non-HIV

Native human monoclonal antibodies with potent cross-lineage neutralization of influenza B viruses

Antimicrob Agents Chemother.

Vigil A, Estélles A, Kauvar LM, Johnson SK, Tripp RA, Wittekind M

doi: 10.1128/AAC.02269-17.

Viral Infections, Non-HIV

A phase III, open-label, single-arm, study to evaluate the safety and immunogenicity of a trivalent, surface antigen inactivated subunit influenza virus vaccine produced in mammalian cell culture (Optaflu®) in healthy adults

Infection.

Loebermann M, Fritzsche C, Geerdes-Fenge H, Heijnen E, Kirby D, Reisinger EC

doi: 10.1007/s15010-018-1233-2.

Viral Infections, Non-HIV

Clinical characteristics, evolution, and treatment-related risk factors for mortality among immunosuppressed patients with influenza A (H1N1) virus admitted to the intensive care unit

J Crit Care.

Garnacho-Montero J, León-Moya C, Gutiérrez-Pizarraya A, Arenzana-Seisdedos A, Vidaur L, Guerrero JE, Gordón M, Martín-Loeches I, Rodriguez A; on Behalf GETGAG Study Group

doi: 10.1016/j.jcrc.2018.08.017.

Viral Infections, Non-HIV

Influenza virus-related critical illness: pathophysiology and epidemiology

Crit Care.

Kalil AC, Thomas PG

doi: 10.1186/s13054-019-2539-x.

Viral Infections, Non-HIV

Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial

Lancet Respir Med.

Vesikari T, Kirstein J, Devota Go G, Leav B, Ruzycky ME, Isakov L, de Bruijn M, Oberye J, Heijnen E

doi: 10.1016/

Viral Infections, Non-HIV

The role of extracellular histones in influenza virus pathogenesis

Am J Pathol.

Ashar HK, Mueller NC, Rudd JM, Snider TA, Achanta M, Prasanthi M, Pulavendran S, Thomas PG, Akhilesh R, Malayer JR, Ritchey JW, Rajasekhar R, Chow VT, Esmon CT, Teluguakula N

doi: 10.1016/j.ajpath.2017.09.014.

Viral Infections, Non-HIV

Detection of Influenza A(H3N2) Virus RNA in Donated Blood

Emerg Infect Dis.

Dos Santos Bezerra R, de Melo Jorge DM, Castro ÍA, Moretto EL, Scalon de Oliveira L, Ubiali EMA, Covas DT, Arruda E, Kashima S, Slavov SN

doi: 10.3201/eid2607.200549.

Viral Infections, Non-HIV

Predominance of influenza virus A(H3N2) 3C.2a1b and A(H1N1)pdm09 6B.1A5A genetic subclades in the WHO European Region, 2018-2019

Vaccine.

Melidou A, Hungnes O, Pereyaslov D, Adlhoch C, Segaloff H, Robesyn E, Penttinen P, Olsen SJ, European Region influenza surveillance network.

doi: 10.1016/j.vaccine.2020.06.031.

Related content

Anti-influenza virus activity of a salcomine derivative mediated by inhibition of viral RNA synthesis

Native human monoclonal antibodies with potent cross-lineage neutralization of influenza B viruses

A phase III, open-label, single-arm, study to evaluate the safety and immunogenicity of a trivalent, surface antigen inactivated subunit influenza virus vaccine produced in mammalian cell culture (Optaflu®) in healthy adults

Clinical characteristics, evolution, and treatment-related risk factors for mortality among immunosuppressed patients with influenza A (H1N1) virus admitted to the intensive care unit

Influenza virus-related critical illness: pathophysiology and epidemiology

Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial

The role of extracellular histones in influenza virus pathogenesis

Detection of Influenza A(H3N2) Virus RNA in Donated Blood

Predominance of influenza virus A(H3N2) 3C.2a1b and A(H1N1)pdm09 6B.1A5A genetic subclades in the WHO European Region, 2018-2019